These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 16497492)
1. Statistical analysis of combined dose effects for experiments with two agents. Wagenpfeil S; Treiber U; Lehmer A Artif Intell Med; 2006 May; 37(1):65-71. PubMed ID: 16497492 [TBL] [Abstract][Full Text] [Related]
2. Interaction index and different methods for determining drug interaction in combination therapy. Lee JJ; Kong M; Ayers GD; Lotan R J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Zhao L; Wientjes MG; Au JL Clin Cancer Res; 2004 Dec; 10(23):7994-8004. PubMed ID: 15585635 [TBL] [Abstract][Full Text] [Related]
4. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428 [TBL] [Abstract][Full Text] [Related]
5. Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves. Fang HB; Tian GL; Li W; Tan M J Biopharm Stat; 2009 Jul; 19(4):625-40. PubMed ID: 20183430 [TBL] [Abstract][Full Text] [Related]
6. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027 [TBL] [Abstract][Full Text] [Related]
7. Isobologram analysis of triple therapies. Niyazi M; Belka C Radiat Oncol; 2006 Oct; 1():39. PubMed ID: 17044920 [TBL] [Abstract][Full Text] [Related]
8. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Wigington DP; Urben CM; Strugnell SA; Knutson JC Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895 [TBL] [Abstract][Full Text] [Related]
9. A two-stage stepwise estimation procedure. Chen JT Biometrics; 2008 Jun; 64(2):406-12. PubMed ID: 18325070 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line MCF-7. Karaca B; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R J BUON; 2009; 14(3):479-85. PubMed ID: 19810142 [TBL] [Abstract][Full Text] [Related]
11. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses. Fang HB; Ross DD; Sausville E; Tan M Stat Med; 2008 Jul; 27(16):3071-83. PubMed ID: 18186545 [TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Pinto AC; Moreira JN; Simões S Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815 [TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of macrocyclic taxane analogues. Tarrant JG; Cook D; Fairchild C; Kadow JF; Long BH; Rose WC; Vyas D Bioorg Med Chem Lett; 2004 May; 14(10):2555-8. PubMed ID: 15109650 [TBL] [Abstract][Full Text] [Related]
16. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines. Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354 [TBL] [Abstract][Full Text] [Related]
17. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217 [TBL] [Abstract][Full Text] [Related]
18. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role? Ostacolo L; Marra M; Ungaro F; Zappavigna S; Maglio G; Quaglia F; Abbruzzese A; Caraglia M J Control Release; 2010 Dec; 148(2):255-63. PubMed ID: 20816710 [TBL] [Abstract][Full Text] [Related]
19. The benchmark dose method--review of available models, and recommendations for application in health risk assessment. Filipsson AF; Sand S; Nilsson J; Victorin K Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105 [TBL] [Abstract][Full Text] [Related]
20. Growth and DNA damage-inducible transcription factor 153 mediates apoptosis in response to fenretinide but not synergy between fenretinide and chemotherapeutic drugs in neuroblastoma. Corazzari M; Lovat PE; Oliverio S; Pearson AD; Piacentini M; Redfern CP Mol Pharmacol; 2003 Dec; 64(6):1370-8. PubMed ID: 14645667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]